Skip to content

Haemonetics HAE Remainder of 2026

Remainder of 2026 at other companies

Abbott logo
AbbottABT
Medtronic logo
MedtronicMDT
ICU Medical logo
ICU MedicalICUI
ITG
Integer HoldingsITGR
Solventum logo
SolventumSOLV
Revvity logo
RevvityRVTY

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.31B-18.0%

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.

The official record: Haemonetics’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's remainder of 2026.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's remainder of 2026?
Haemonetics (HAE) reported remainder of 2026 of $12.32M in Q4 2025.
How has Haemonetics's remainder of 2026 changed year-over-year?
Haemonetics's remainder of 2026 decreased by 5.2% year-over-year, from $13M to $12.32M.